Los Gatos, CA (PRWEB) February 11, 2014
Annai Systems Inc., a genomic data management solution provider, today announced that David Szekeres has joined the company’s Board of Directors.
Mr. Szekeres was recently named Chief Business Officer and General Counsel at Regulus Therapeutics after having served as Deputy General Counsel, Chief M&A Counsel and Assistant Secretary at Life Technologies Corporation (recently sold to Thermo Fisher). At Life Technologies Mr. Szekeres led more than fifty transactions valued at over $30 billion, including leading the acquisition of Ion Torrent to expand Life’s genomics business. He was also responsible for all legal functions in the areas of corporate transactions, corporate governance, SEC reporting and compliance. Prior to his years at Life, Mr. Szekeres held positions of increasing responsibility at a number of prestigious law firms, including Latham & Watkins LLP, O’Melveny & Myers LLP and Dechert LLP. Mr. Szekeres began his career in the investment banking group at Robertson Stephens. Mr. Szekeres also serves on the boards of directors of Anochi BioPharma and the San Diego chapter of the Association of Corporate Counsel. Mr. Szekeres holds a B.A. from the University of California at Irvine and a J.D. from Duke University.
“We are delighted to welcome David to the Annai Systems Board and are excited to be working with this strategic business leader to deliver on Annai’s goals and contribute to the advancement of genomic medicine,” said Michael Penley, Annai Systems’ Chief Executive Officer. “The experience that David brings to our Board will be invaluable as we continue to evolve our strategies and execute on achieving our goals, as the application of genomic data to personalized medicine continues to progress at an explosive pace.”
About Annai Systems
Annai Systems Inc., with offices in California’s Silicon Valley and Carlsbad California, is a technology company with a core competency in big data management solutions. We are focused on applying our technology to the field of genomics to enable easier, more efficient access to genomic data. Our technology enables the producers and consumers of genomic data to achieve better results faster and at lower operating costs by providing products that overcome key data-related bottlenecks and roadblocks that are impeding progress in the growing fields of genomic research and medicine. Annai Systems offers a variety of products and services to address the “big data” challenges associated with using genomic data in personalized medicine and healthcare improvement. http://www.annaisystems.com
Source: Annai Systems Inc.
Annai Systems Inc. Investors or Media: Jay Kaufman 650 400-5812, firstname.lastname@example.org